The research unit led by Professor Briganti is dedicated to advancing various innovative and impactful areas within urology. The primary research areas include health outcomes, prostate cancer, novel imaging modalities, and the integration of artificial intelligence in urology. A significant focus of the unit is health outcomes research. The goal is to improve patient care and treatment strategies through rigorous data analysis, which involves evaluating the effectiveness of various urological treatments and interventions to ensure optimal patient outcomes. Prostate cancer is a central focus of the unit, with extensive research aimed at understanding the disease's progression, treatment options, and outcomes. This research includes investigating both surgical and non-surgical treatments to identify the most effective approaches for managing prostate cancer. A key area of investigation is the development and implementation of novel imaging modalities, particularly PSMA PET scans. These advanced imaging techniques are crucial for accurate diagnosis and staging of prostate cancer, allowing for more precise and personalized treatment plans. The unit is also at the forefront of integrating artificial intelligence into urological practice. Current research explores how AI can predict outcomes for patients undergoing surgical interventions. Additionally, Professor Briganti’s research unit is leading the XEOS trial, which focuses on intraoperative PSMA PET imaging to enhance the precision of prostate cancer surgeries by providing real-time imaging during procedures. This trial aims to improve surgical outcomes and reduce the likelihood of cancer recurrence. Another major project under Professor Briganti’s leadership is the QUANTIB prostate trial. This study investigates the application of artificial intelligence in prostate imaging to improve the accuracy and efficiency of prostate cancer diagnosis and treatment. The research unit extensively utilizes the URI database, which includes data from over 11,000 prostate cancer patients. This extensive repository of clinical information supports large-scale studies to identify trends, outcomes, and potential improvements in prostate cancer treatment. Furthermore, the unit plays a pivotal role in major European projects such as PIONEER and OPTIMA. These initiatives aim to harmonize and integrate data across different studies and institutions, advancing the understanding and management of prostate cancer on a broader scale.

Click here to view our publications